PropertyValue
?:abstract
  • BACKGROUND Since the outbreak of the COVID-19, numerous therapies to counteract severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored. METHODS A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: \'Tocilizumab,\' \'Actemra,\' \'COVID-19.\' An additional sub-search was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials. RESULTS A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR=0.42, 95% CI=0.26 to 0.69, P-value=0.0005, I2=55%). A descriptive analysis of 50 registered trials was conducted. CONCLUSION This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.
?:creator
?:doi
?:doi
  • 10.3906/sag-2010-131
?:journal
  • Turkish_journal_of_medical_sciences
?:license
  • unk
?:pmid
?:pmid
  • 33244947
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Tocilizumab and COVID-19: A Meta-Analysis of 2120 Patients with Severe Disease and Implications for Clinical Trial Methodologies.
?:type
?:year
  • 2020-11-27

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/7pqnnshp>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/7pqnnshp>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all